Key result
Chronic hyperviscosity contributes to the pathogenesis of atherosclerosis, hypertension, and metabolic syndrome, while therapeutic phlebotomy may reduce blood pressure and serum glucose levels.
Design
Review
Authors
Loading...
Hyperviscosity may be a cardiometabolic target; leaves open whether phlebotomy improves outcomes without randomized trials.
This review highlights the often-overlooked role of blood viscosity in cardiovascular diseases and suggests it as a potential therapeutic target.
Sloop et al. (2014) conducted a review in Cardiovascular diseases (atherosclerosis, hypertension, metabolic syndrome). Chronic hyperviscosity was evaluated. Chronic hyperviscosity contributes to the pathogenesis of atherosclerosis, hypertension, and metabolic syndrome, while therapeutic phlebotomy may reduce blood pressure and serum glucose levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: